Analysts Are Bullish on Top Healthcare Stocks: Boston Scientific (BSX), Jazz Pharmaceuticals (JAZZ)

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSXResearch Report), Jazz Pharmaceuticals (JAZZResearch Report) and Adocia SA (ADOIFResearch Report) with bullish sentiments. Boston Scientific (BSX) In a report issued on October 26, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Boston Scientific, with a price target of $50.00. The companys shares closed last Thursday at $41.58.

According to TipRanks.com, Chadha s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.9% and a 30.4% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Edwards Lifesciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $48.85 average price target, representing a 16.8% upside. In a report issued on October 11, Jefferies also initiated coverage with a Buy rating on the stock with a $50.00 price target.

See today’s best-performing stocks on TipRanks >> Jazz Pharmaceuticals (JAZZ) RBC Capital analyst Gregory Renza maintained a Buy rating on Jazz Pharmaceuticals on October 26 and set a price target of $206.00. The companys shares closed last Thursday at $141.35.

According to TipRanks.com, Renza is a 1-star analyst with an average return of -2.3% and a 33.7% success rate. Renza covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Pacira Pharmaceuticals, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $193.50 average price target, representing a 37.2% upside. In a report issued on October 14, Bank of America Securities also maintained a Buy rating on the stock with a $183.00 price target.

Adocia SA (ADOIF) Kepler Capital analyst Arsene Guekam maintained a Buy rating on Adocia SA on October 26 and set a price target of EUR12.00.

According to TipRanks.com, Guekam is a 1-star analyst with an average return of -3.3% and a 31.8% success rate. Guekam covers the Healthcare sector, focusing on stocks such as Innate Pharma SA, Quantum Genomics, and Guerbet SA.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adocia SA with a $12.09 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on BSX:

Leave a Reply

Your email address will not be published. Required fields are marked *